Roussel-Uclaf's mifepristone (RU 486)
Executive Summary
Roussel-Uclaf's mifepristone (RU 486): Study by Beatrice Couzinet, MD, et al, reported in the Dec. 18 issue of the New England Journal of Medicine finds that RU 486 caused termination of early pregnancy in 85% of 100 study participants. Investigators conclude that "the high frequency of complete abortion suggests that the efficacy of the drugt increases with shorter length of gestation." The study was limited to the first 10 days after expected onset of the missed menstrual period. Prolonged uterine bleeding occurred in 18% of the women. Couzinet, et al, note that the success rate with prostaglanding also approaches 85% but adds that prostaglandins are "associated with painful uterine contractions and gastrointestinal side effects in approximately 50% of subjects".
You may also be interested in...
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.